| The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors. The performance of mpMRI can vary depending on the population being studied, the execution of the MRI itself, the experience of the radiologist, whether additional biomarkers are considered and whether mpMRI-targeted biopsy is carried out alone or in addition to systematic biopsy. A number of challenges to implementation remain, such as ensuring high-quality execution and reporting of mpMRI and ensuring that this diagnostic pathway is cost-effective. Nevertheless, emerging clinical trial data support the adoption of this technology as part of the standard of care for the diagnosis of prostate cancer. *Department of radiology, nyu langone Health, new york, ny, uSa. 6 Department of urology, nyu langone Health, new york, ny, uSa.
Prostate cancer is the most common solid organ malignancy among men worldwide 1, 2 . The lifetime probability of a man developing prostate cancer is 1 in 9 and the number of estimated deaths caused by prostate cancer in the USA during 2018 was 29,430 (ref. 2 ). To date, the use of serum PSA level and/or an abnormal digital rectal examination (DRE) followed by random transrectal ultrasonography (TRUS)-guided prostate biopsy has been the traditional diagnostic pathway for prostate cancer 3 .
The evidence regarding the benefit of populationbased serum PSA screening for prostate cancer is contradictory [4] [5] [6] . However, the US Preventive Services Task Force (USPSTF) recommendations against PSA screening 7 , issued in 2012, were followed by a subsequent increase in the incidence of high-grade and locally advanced tumours 8 . Results from two meta-analyses of subsequent randomized studies demonstrated that PSA screening leads to a small reduction in the risk of dying from prostate cancer over 10 years 9, 10 . Taken together, these findings led the USPSTF to update its recommendation in 2018, suggesting that men aged between 55 and 69 years should have a choice as to whether to undergo PSA-based screening 11 . These findings also led the European Association of Urology to support the use of PSA as a screening tool in 2019 (ref. 12 ). The current goldstandard test for prostate cancer diagnosis -12-core TRUS-guided biopsy for men with elevated serum PSA levels 13 -is affected by sampling error, which can lead to failure to detect clinically significant prostate cancer, imprecise risk stratification and detection of clinically insignificant prostate cancer 14 with a considerable rate of false-negative results 15 . Prostate cancer mortality has rapidly declined 2 in the past few decades, but this reduction is probably only partly related to the extensive use of PSA screening, and random biopsies and other factors (such as advances in therapeutic strategies) have contributed to increased survival 16 . These factors combined suggest that the standard-of-care approach to prostate cancer diagnosis -serum PSA screening followed by TRUS-guided biopsy -has led to overdiagnosis (of up to 45% of men diagnosed with prostate cancer) and overtreatment of low-volume and indolent tumours 5, 17 . Moreover, the use of TRUS-guided biopsy is associated with missed diagnosis of clinically significant prostate cancer in up to 30% of cases 18 . Thus, an improvement in the diagnostic pathway for prostate cancer is needed in order to decrease both misdiagnosis of clinically significant prostate cancer and overdiagnosis of clinically insignificant prostate cancer.
Abnormal multiparametric MRI (mpMRI) is positively associated with increased tumour volume and high tumour grade 19 ; thus, the introduction of this modality into the diagnostic pathway would hopefully assist in the mitigation of both overdiagnosis and underdiagnosis. This purpose was the intended role of mpMRI when it was introduced in the early 1980s for improving the staging of prostate cancer 20 . However, through refinement in the use of mpMRI sequences and the development of Multiparametric MRI for prostate cancer diagnosis: current status and future directions reporting systems 21 , owing to the use of mpMRI-targeted biopsies 22 , mpMRI soon gained an important role in prostate cancer detection 19 , conferring information on the cancer that had to date been missing, such as volume, location and multifocality.
In this Review, we describe the current status of the role of mpMRI in prostate cancer diagnosis, starting with the basic principles of MRI and its clinical application, and finally consider the future direction of this technology in prostate cancer.
Basics of mpMRI Principles and sequences
When mpMRI was first considered for prostate cancer diagnosis, in the mid-1980s, its use was focused on T1-weighted and T2-weighted sequences 23 . The rapid improvement of mpMRI technology has led to the addition of further sequences such as diffusion-weighted imaging (DWI), dynamic contrast-enhanced imaging (DCEI) (figs 1,2) and/or magnetic resonance spectroscopy imaging (MRSI) 23 (figs 2,3). These advances resulted in a multitude of contrast mechanisms that can be considered together for improved diagnostic accuracy for prostate cancer 24 .
T1-weighted imaging. T1-weighted imaging is used mainly for evaluation of regional lymph nodes and bone structures 25 . In the context of prostate evaluation, its utility is the ability to detect biopsy-related haemorrhage that can obscure or mimic cancers 26 . In order to reduce post-biopsy artefacts, a delay of at least 6-8 weeks after biopsy is typically recommended. Currently, no consensus exists concerning this clinical practice; indeed, haemorrhage artefacts can still persist beyond this period 25 . This sequence is of limited value for detection of prostate cancer foci, as the presence of prostate cancer is not associated with notable T1-weighted imaging changes 21 .
T2-weighted imaging. T2-weighted imaging is a fundamental sequence in mpMRI of the prostate, providing a highly defined anatomical image of the zonal architecture of the prostate gland with excellent soft-tissue contrast 27 ( fig. 4 ). T2-weighted imaging reflects the water content of the tissue, which is related to the cellularity 21 .
In the normal prostate, the peripheral zone -the part of the prostate present at birth -appears homogeneously hyperintense on T2-weighted imaging owing to its high glandular ductal tissue content 21 . Prostate cancer is characterized by high cellularity and low water content and, therefore, will appear hypointense on imaging 21 ( fig. 2Aa,2Ba ). The decrease in intensity is positively associated with the aggressiveness of cancer 28 . The transition zone, which starts to form after puberty through the process of prostatic epithelial and stromal hyperplasia, tends to exhibit high cellular density and appears heterogeneously hypointense 25 . For this reason, and because there is no non-malignant prostate against which to reference (as every prostate is morphologically unique), cancer detection on T2-weighted imaging within the transition zone is challenging. Moreover, other changes such as acute and chronic prostatitis, scars, irradiation, hormonal treatment effects and postbiopsy haemorrhage might mimic prostate cancer on T2-weighted imaging 26 . The utility of this sequence in prostate cancer diagnosis is in discerning prostatic zonal anatomy and identifying suspicious areas through the analysis of anatomical characteristics and hypointensity level.
Diffusion-weighted imaging. DWI quantifies the degree of random movement of water molecules within tissue 29 . Within nonmalignant prostatic tissue, the water molecules move relatively freely, but in cancerous prostate tissue the motion of water molecules is strongly inhibited owing to the increased volume of the glandular epithelium and the high cellularity 29 . Thus, the apparent diffusion coefficient (ADC), which reflects the capability of water to move, will be lower in areas affected by prostate cancer than in healthy tissue. The ADC map is obtained by performing DWI with multiple magnetic gradient strengths (b values). Increased b values (minimum highest b values of 1400 s/mm 2 and 2000 s/mm (ref. 2 ) for 1.5 T and 3 T, respectively 25 ), obtained by reducing the background signal from the nonmalignant prostate tissue, have been demonstrated to increase the sensitivity and the accuracy of prostate cancer detection (88% versus 71% and 89% versus 86%, respectively) 30 . Suspicious areas appear as a bright spot surrounded by low signal tissue on DWI 25 (fig. 2Ab,2Bb) ; conversely, on the ADC map, prostate cancer appears as a low-signal area ( fig. 2Ac,2Bc) with the degree of signal decrease positively associated with increasing Gleason score 31 .
Key points
• multiparametric mrI (mpmrI) of the prostate is a novel promising tool for diagnosis of prostate cancer that might help to reduce overdiagnosis of insignificant prostate cancer. • mpmrI should include four sequences: T1-weighted images, T2-weighted images, diffusion-weighted images (DWI) and dynamic contrast-enhanced imaging (DCeI). • Interpretation and reporting of mpmrI must be carried out following standardized scoring systems (such as Prostate Imaging reporting and Data System (PI-raDS) v2). • The use of mpmrI is considered useful; the use of mpmrI-targeted biopsy is increasing the detection of clinically significant prostate cancer in both biopsy-naive and previous negative biopsy settings. • The use of mpmrI as a triage test is still controversial. In men with negative mpmrI, omitting a biopsy can only be considered when the clinical suspicion of prostate cancer is low. • Improvements in inter-reader agreement, development of computer-aided diagnostic systems and assessment of biomarkers to use in combination with mpmrI are needed.
The use of DWI in combination with T2-weighted imaging results in higher sensitivity (0.76) and specificity (0.82) than T2-weighted imaging alone for detecting prostate cancer 24 and also improved characterization of transition-zone tumours 32 . The transition zone is more likely to harbour benign prostatic hyperplasia nodules than other prostate zones and is often hypointense at T2-weighted sequences. The addition of DWI helps considerably in discerning malignant nodules 25 .
Dynamic contrast-enhanced imaging. The aim of using the DCEI sequence is to assess the status of tumour angiogenesis on the basis of the evaluation of differences in the velocities and intensities of contrast agent uptake and washout by malignant and non-malignant prostatic tissue 33 . DCEI is generated by rapid acquisition of a series of T1-weighted images after intravenous injection of a Ga-based contrast agent. This modality enables the evaluation of both the intensity and the dynamics of contrast enhancement. Early enhancement (appearance in the T1-weighted images obtained) of increased intensity is the hallmark feature of cancer 33 ( fig. 2Ad,2Bd ). Nonetheless, as with other sequences, other benign conditions (such as hyperplastic nodules and prostatitis) might have these characteristics and lead to false-positive results. DCEI alone has a reported sensitivity and specificity for the detection of prostate cancer of 46-90% and 74-96%, respectively 34 . Even though the use of DCEI is currently debated, mainly owing to the increased costs and the duration of MRI related to the use of gadolinium, as well as the reported data supporting the value of biparametric MRI (on the basis of only T2-weighted and DWI) 35, 36 , DCEI seems to be particularly useful when T2-weighted and DWI are equivocal or degraded by artefacts. In this context, DCEI has demonstrated an important role in the evalua tion of local recurrence after interventions (such as transurethral resection of the prostate and focal therapy) that change prostate morphology, creating a setting in which standard reporting systems (for example, Prostate Imaging Reporting and Data System (PI-RADS) score) are not applicable 25, 37, 38 .
Magnetic resonance spectroscopy imaging. MRSI sequences visualize the pattern of expression of specific metabolites, such as citrate and choline 39 . Citrate is normally produced by nonmalignant prostatic tissue but its expression is decreased in prostate cancer cells. Conversely, choline (an important constituent of cell membrane) levels are low in nonmalignant tissue but high in prostate cancer 39 . Evaluating the relative change in these metabolites enables detection of areas of the prostate likely to harbour cancer. The sensitivity of MRSI alone ranges from 75% to 89% and the specificity from 77% to 91% 40 . MRSI is not currently widely used in routine clinical practice and is primarily used in academic centres or research studies primarily because of related costs, availability and lack of evidence supporting its extensive use. Dedicated software is required for signal analysis. In the context of functional sequences, a quantitative correlation between prostate cancer aggressiveness and MRSI, ADC and DCEI has been shown 31, [41] [42] [43] ( fig. 3 ). Although not currently used, these sequences could have a specific role in providing a noninvasive tool for risk stratification. Further prospective studies assessing the role of MRSI in combination with other mpMRI sequences are needed in order to clarify its role in prostate cancer diagnosis.
Interpretation
One of the most considerable challenges in prostate mpMRI has been the development of a standardized reporting system. mpMRI is typically reported using a Likert scale, which reflects the probability of the presence of prostate cancer. Initially, the criteria used to ascribe a Likert score were most often based on the radiologist's subjective opinion 23 . When a Likert score of suspicion was derived in this manner the scoring system used was often termed the Likert scoring system. As this reporting system was based on the experience of the radiologist reporting the mpMRI, this method was inevitably affected by a high rate of variability in interpretation and lack of reliability. In order to reduce the inter-reader disagreement, decrease the gap between differently skilled radiologists and centres and improve communication between radiologists and urologists, the PI-RADS v1 was developed in 2012, which applied a set of rigid criteria to assign specific scores of suspicion 21 . This classification system was the first attempt to standardize prostate mpMRI reporting. PI-RADS v1 consisted of a five-point suspicion scale (PI-RADS 1 = very low suspicion to PI-RADS 5 = very high suspicion) for each sequence used, including T2-weighted imaging, DWI, DCEI and MRSI, and the total score depended 25 in an attempt to overcome the issues related to the PI-RADS v1. First, a specific algorithm was provided to assign a final score to a lesion that had been detected. Second, the interpretation of each sequence was substantially simplified, particularly for DCEI. These first two changes were intended to overcome poor reporting reproducibility and improve time efficiency. Third, to improve mpMRI diagnostic accuracy, dominant sequences for different prostatic areas were defined (such as T2-weighted imaging for the transition zone and DWI for the peripheral zone). Finally, MRSI was no longer included in the scoring workflow, to make the PI-RADS score even more widely applicable. A meta-analysis reported a significant improvement in prostate cancer detection using PI-RADS v2 compared with PI-RADS v1 in terms of sensitivity (0.95 versus 0.88, P = 0.04) but no significant differences in specificity (0.73 versus 0.75, P = 0.90) 45 , suggesting an improvement in the ability of mpMRI to detect prostate cancer and stability in the rate of false positives.
The PI-RADS scoring systems are widely used in clinical practice, but some experienced radiologists prefer the subjective Likert scoring system as they value the ability to score outside of the rigid criteria of the PI-RADS scoring system because not all situations fit the PI-RADS scoring criteria perfectly. For example, the DWI sequence could be suboptimal or lesions might only be identified using contrast-enhanced sequences, which would lead to a low score of suspicion using PI-RADS v2 but a higher score of suspicion using the Likert scoring system. In a 2018 multicentre analysis 46 , the central quality control of mpMRI identified that, despite using PI-RADS v2 for scoring mpMRI, the agreement between central reading and local site reading was similar to that of a multicentre study using the Likert scoring system 47 . This observation might suggest that inter-reader agreement of Likert and PI-RADS score are comparable, but this assumption needs to be confirmed with a dedicated prospective study.
In studies comparing the performance of PI-RADS scoring systems with the Likert scoring system, some have shown that the Likert scoring system performs similarly 48 or better than PI-RADS scoring systems 49, 50 , but these studies were carried out in centres with experienced radiologists and might not be reproducible in centres in which the radiologists have less experience 49, 50 . Some room for improvement clearly exists in the standardization of reporting of prostate MRI, and the PI-RADS v2 scoring system provides a good starting point for radiologists learning how to interpret prostate MRI. Future improvements need to cover interobserver agreement, clarification and simplification of the scoring workflow and refinement of technical issues concerning mpMRI acquisition.
Indications
The introduction of mpMRI to the clinical pathway of prostate cancer diagnosis is an ongoing process and international guidelines have been updated. For example, the European Association of Urology (EAU) guidelines on prostate cancer suggest that mpMRI could be used in two www.nature.com/nrurol different ways: first, to improve the detection of clinically significant prostate cancer by adding targeted biopsy to systematic biopsies in instances of positive mpMRI results and performing systematic biopsies alone when mpMRI is negative. Second, as a triage test before biopsy, in which a targeted biopsy alone would be performed when mpMRI is positive and patients with a negative mpMRI would not undergo any prostatic biopsy 3 . The role of mpMRI is slightly different for each biopsy setting. In biopsy-naive patients, a positive scan would improve the definition of the suspicious area and enable a targeted biopsy to be performed. Conversely, a negative mpMRI might enable men to defer or avoid biopsy. In the setting of a previous negative biopsy, a positive mpMRI could help in sampling a lesion that might have been missed at the previous biopsy. In patients with a previous diagnosis of low-risk prostate cancer, mpMRI might improve the risk assessment and help in decision-making between active surveillance and definitive treatment.
The EAU guidelines on prostate cancer 3 and the National Comprehensive Cancer Network (NCCN) guidelines on early detection of prostate cancer 51 state that evidence is insufficient to recommend routine use of mpMRI in biopsy-naive men. Nonetheless, agreement exists regarding the helpful role of mpMRI in this setting, with EAU guidelines on prostate cancer strongly recommending the use of the combination of targeted and TRUS-guided biopsies in instances of positive mpMRI 3 . Both guidelines agree, with a high grade of recommendation 52 , on performing mpMRI before a repeat biopsy when clinical suspicion persists. Regarding active surveillance, the EAU guidelines do not recommend the use of mpMRI as a standalone tool to trigger biopsy; nonetheless, its use before confirmatory biopsy is suggested, with a high grade of recommendation 3, 52 . Similarly, the NCCN guidelines for prostate cancer support the use of mpMRI and MRI-targeted biopsy, but the inclusion of mpMRI in the active surveillance protocol is still considered controversial 51 .
A further use of mpMRI is for the local staging of prostate cancer; mpMRI can be useful in assessing T stage to help determine whether disease is confined to the gland or has spread beyond it. The PI-RADS v2 naTure revIeWS | UROlOgY guidelines highlight involvement of the neurovascular bundle, asymmetry of the bundles, bulging of the contour of the prostate, irregular margin and loss of the rectoprostatic angle as signs suggestive of extraprostatic involvement 25 . mpMRI can also be used to assess seminal vesicle involvement, with low T2-weighted signal, restricted diffusion or contrast enhancement suggesting seminal vesicle involvement 25 . mpMRI might also help to identify abnormal lymph nodes and pelvic skeletal metastasis, specifically through anatomical cross-sectional evaluation and DCEI sequence. Nonetheless, these specific evaluations are not included in a standardized reporting method such as PI-RADS. Notably, current guidelines do not typically necessitate mpMRI in patients with low-risk disease and predominant Gleason score 3 pattern for local staging 3 . The main reason is the low sensitivity for extracapsular extension (ECE; 0.49-0.64), particularly for focal ECE 53 . However, in patients with low-risk disease, mpMRI might be used if nerve-sparing surgery is considered to rule out any eventual macroscopic area of ECE, although evidence that conclusively demonstrates the benefit of mpMRI over existing staging tools is still awaited. Indeed, evidence suggests that patients with low-risk disease might not benefit from preoperative mpMRI 54 with this test having no incremental value compared with other standard staging tools 55 . Moreover, the use of preoperative mpMRI does not seem to affect the rate of positive surgical margins 56 . However, in patients with high-risk disease, the high specificity of mpMRI makes this test a useful tool in preoperative assessment, given the increased probability of ECE 55 .
Current role of mpMRI in diagnosis
When assessing the diagnostic performance of mpMRI in the detection of prostate cancer, two main factors must be taken into account: first, the reporting system used has changed and developed over time and is often different in different studies, making comparison challenging. Second, the reference standard considered to prove the presence of cancer (such as systematic biopsy, systematic plus targeted biopsy and radical prostatectomy) needs to be considered when comparing different diagnostic strategies.
De Rooij and colleagues 57 published the first metaanalysis investigating the accuracy of the combination of T2-weighted imaging and two functional techniques, DWI and DCEI, before publication of PI-RADS v1. The authors evaluated seven studies summarizing results from 526 patients. The studies in which the whole prostate was analysed showed a pooled sensitivity of 0.78 (95% CI 0.65-0.87) and a pooled specificity of www.nature.com/nrurol 0.88 (95% CI 0.80-0.94). The reference standard was standard TRUS biopsy or transperineal biopsy without any targeted approach in five studies and radical prostatectomy in the other two, and the scoring systems used varied considerably 57 . The first meta-analysis of studies analysing PI-RADS v1 included 14 studies and 1,785 patients 44 . The majority of studies included a targeted biopsy approach as the reference standard with one exception that used radical prostatectomy. The pooled sensitivity and specificity were 0.78 and 0.79, respectively. Negative predictive value (NPV) and positive predictive value (PPV) ranges were 0.58-0.96 and 0.50-0.83, respectively. Studies with a low risk of bias regarding PI-RADS applica bility showed better performance than those with a high risk of bias (sensitivity of 0.82 versus 0.73 and specificity of 0.82 versus 0.75). Moreover, mpMRI sensitivity was increased (0.84) and specificity reduced (0.75) when clinically significant prostate cancer was considered as the outcome instead of any prostate cancer, suggesting an increased false-positive rate and a reduced false-negative rate 44 .
After the release of PI-RADS v2 in 2015, Woo et al. 45 published a meta-analysis in which the performance of mpMRI was evaluated and compared with PI-RADS v1. For all the 21 studies included (3,857 men), the pooled sensitivity and specificity were 0.89 (range 0.73-1.00) and 0.73 (range 0.80-1.0), respectively. Direct comparison of PI-RADS v1 with v2 showed that PI-RADS v2 had increased pooled sensitivity (0.95) but no differences in specificity. In terms of choosing a cut-off PI-RADS score for indicating a suspicious mpMRI, regardless of the PI-RADS version used, a score of ≥4 provided acceptable sensitivity (0.89) and specificity (0.74); however, a cut-off score of ≥3 provided an excellent sensitivity (0.95) but a poor specificity (0.47) 45 . The authors suggested that use of ≥4 as a cut-off value could be adequate for the general use of PI-RADS, and the latter PI-RADS ≥3 might be considered in men with previous negative biopsies, in whom missing as few cancers as possible (that were potentially missed during the previous prostate biopsy) is desirable. In localizing prostate cancer, PI-RADS v2 had better sensitivity for cancers in the peripheral zone than for those in the transition zone (0.93 versus 0.88), but specificity was lower (0.68 versus 0.75) 45 , underlining the more challenging interpretation when characterizing the transition zone in mpMRI images.
Another systematic review that assessed the accuracy of mpMRI for the detection of clinically significant prostate cancer reported a detection rate ranging from 44% to 87% 19 , which is considerably higher than for random TRUS biopsies, even when extended sampling is taken into account (detection rate of any cancer of 42.5% using 21-core TRUS-guided biopsies) 58 .
Evaluating the diagnostic yield of mpMRI-targeted biopsies compared with systematic biopsies is important when assessing the performance of mpMRI for detecting prostate cancer. In the past 4 years, several studies have compared targeted biopsy and systematic biopsy approaches. In a systematic review including 14 studies (involving 2,293 patients), median detection of clinically significant prostate cancer was 24% for TRUS-guided biopsy and 33% for mpMRI-targeted biopsy and median detection of any prostate cancer was 43% for TRUSguided biopsy and 51% for mpMRI-targeted biopsy 59 . In 10 of 14 studies, mpMRI-targeted biopsy detected less clinically insignificant disease than TRUS-guided biopsy. Moreover, a targeted approach was more efficient, detecting more clinically significant disease with fewer cores (9 versus 37). The proportion of clinically significant prostate cancer missed using TRUS-guided biopsy and detected by mpMRI-targeted biopsy was 9% (range 5-16%). Conversely, use of mpMRI-targeted biopsy resulted in 2% of clinically significant prostate cancers being missed (range 0-12%) 59 .
Schoots et al. 22 performed a meta-analysis of 16 strictly selected studies (all men included had a positive mpMRI and received TRUS-guided biopsy and mpMRItargeted biopsy) in order to provide reliable results regarding pooled benefit of mpMRI-targeted biopsy compared with TRUS-guided biopsy in prostate cancer detection. Use of mpMRI-targeted biopsy resulted in 20% more clinically significant prostate cancers being identified than use of TRUS-guided biopsy (P < 0.001) 22 . Furthermore, mpMRI-targeted biopsy was almost twofold better at avoiding detection of insignificant disease (relative sensitivity of 0.56) 22 . These observations show the high accuracy of mpMRI and, importantly, its superiority compared with the standard of care (TRUS-guided biopsy) in detecting clinically significant prostate cancer and avoiding overdiagnosis of insignificant disease.
mpMRI in biopsy-naive patients
The role of a prebiopsy mpMRI in biopsy-naive men might be to identify those with a low risk of harbouring clinically significant prostate cancer who could avoid a biopsy, therefore, reducing the number of biopsies performed on a population level and decreasing overdiagnosis and overtreatment. Evidence is conflicting in this group of men: a subgroup analysis by Schoots and colleagues 22 showed that mpMRI-targeted biopsy and TRUS-guided biopsy had a similar detection rate for clinically significant prostate cancer (relative sensi tivity 0.97). Thus, the authors reasoned that systematic sampling alone might be sufficient to detect prostate cancer. Results of a systematic review showed that use of mpMRI-targeted biopsy was associated with reduced detection of prostate cancer 60 . However, the PROMIS study 47 provided level 1 evidence for diagnostic accuracy of an upfront mpMRI and took a major step towards the introduction of this radiological test in the diagnostic pathway of men in whom prostate cancer is suspected. In this study, mpMRI-targeted biopsy had greater sensitivity than TRUS-guided biopsy (87% versus 60%) and a higher NPV (72% versus 65%) for detecting Gleason score prostate cancer ≥3 + 4 or cancer core length ≥4 mm (ref. 47 ).
In 2018, Kasivisvanathan et al. 46 published the rando mized controlled PRECISION study. In this trial, 500 men in whom prostate cancer was suspected were randomly assigned to receive either mpMRI (group 1) or TRUS-guided biopsy (group 2). Men assigned to group 1 underwent an mpMRI-targeted biopsy alone if their mpMRI was positive, but did not undergo any biopsy if their mpMRI was negative. In group 1, 28% of patients avoided biopsy owing to the absence of any suspicious areas on mpMRI. mpMRI-targeted biopsy aided diagnosis of clinically significant prostate cancer in 38% of men, compared with 26% for TRUS-guided biopsy (P = 0.005) 46 (TABle 1) .
Porpiglia et al. 61 performed a randomized controlled trial (RCT) comparing the combination of TRUS-guided biopsy and mpMRI-targeted biopsy (arm A) with TRUSguided biopsy alone (arm B) in 212 biopsy-naive men. Men with a negative mpMRI in arm A underwent a TRUS-guided biopsy. Detection of any prostate cancer and clinically significant prostate cancer were higher in arm A than in arm B (50.5 versus 29.5% and 43.9 versus 18.1%, respectively, all P < 0.002). Interestingly, within arm A, detection of clinically significant prostate cancer was 56.8% for mpMRI-targeted biopsy alone (in patients with positive mpMRI) and 3.8% for TRUS-guided biopsy alone (in patients with negative mpMRI). These results demonstrated the utility of adding mpMRI to the diagnostic pathway and also the low probability of missing clinically significant prostate cancer and avoiding biopsy when mpMRI is negative 61 . Panebianco et al. 62 conducted a similarly designed RCT in 1,140 patients. In this study, patients underwent either a TRUSguided biopsy (group A) or mpMRI and TRUS-guided biopsy plus eventual subsequent mpMRI-targeted biopsy (group B). Detection of any prostate cancer was higher in the mpMRI group than in the TRUS-guided biopsy group (73% versus 38%) 62 . However, other RCTs have shown different results. Tonttila et al. 63 randomly assigned 113 men to either mpMRI with subsequent TRUS-guided biopsy plus eventual mpMRI-targeted biopsy or to TRUS-guided biopsy. Cancer was detected in 64% of men in the mpMRI arm and in 57% of men in the TRUSguided biopsy arm. Clinically significant prostate cancer was detected in 55% of men in the mpMRI arm and in 45% of men in the TRUS-guided biopsy arm. The differences between the two groups were not statistically significant, but the comparison is likely to be underpowered owing to the small number of patients included 63 (TABle 1) . Baco et al. 64 randomly assigned 175 men either to TRUS-guided biopsy and targeted biopsy of suspicious lesions (at either DRE or ultrasonography) or to TRUSguided biopsy combined with mpMRI-targeted biopsy. No significant differences were found for detection of any prostate cancer between the control group and the mpMRI group (54% versus 59%, respectively, P = 0.4) or for clinically significant prostate cancer (49 versus 44%, respectively, P = 0.5) 64 . Boesen et al. 35 assessed the value of biparametric MRI in 1,020 patients referred for suspected prostate cancer. A combined approach (mpMRI-targeted biopsy plus TRUS-guided biopsy) was restricted to men with suspicious mpMRI findings. The combination improved detection of clinically significant prostate cancer by 11% and reduced detection of insignificant disease by 40% compared with TRUS-guided biopsies in all men (TABle 1) . Rouvière et al. 65 published a prospective multicentre paired cohort study enrolling 275 men with a suspicion of prostate cancer. Each patient received mpMRI and subsequently underwent TRUS-guided biopsy plus eventual mpMRI-targeted biopsy in instances of positive mpMRI. No differences were reported in the detection of clinically significant prostate cancer between mpMRI-targeted and TRUSguided biopsy (32.3% versus 29.9%, P = 0.38). However, the highest detection of clinically significant prostate cancer was reached by a combination of the two techniques (37%). In a similar paired-cohort study, van der Leest et al. 66 compared the detection of clinically significant prostate cancer in an MRI pathway versus a TRUS-guided biopsy pathway in a cohort of 626 men with suspicion of prostate cancer receiving mpMRI and subsequent TRUS-guided biopsy plus eventual mpMRI-targeted biopsy. The MRI pathway (in which patients with a positive mpMRI undergo only mpMRItargeted biopsy and patients with negative mpMRI do not receive any form of biopsy) resulted in a detection rate of 25.4% for clinically significant prostate cancer. The TRUS-guided biopsy pathway (in which all patients receive a TRUS-guided biopsy) resulted in a detection rate of 23.3% for clinically significant prostate cancer (P = 0.17). Detection of insignificant prostate cancer was significantly different between groups (14.1% for mpMRI versus 24.8% for TRUS-guided biopsy, P < 0.0001). Thus, the MRI pathway would have avoided biopsy in 49% of men at the cost of missing 4% of clinically significant prostate cancer.
In key studies with a paired cohort design in the biopsy-naive setting (TABle 1) , four paired cohort studies and one RCT showed higher detection of clinically significant prostate cancer using mpMRI-targeted biopsy than the TRUS-guided biopsy 35, 46, [67] [68] [69] [70] However, two prospective paired-cohort studies 65, 66 showed no significant differences between these two biopsy techniques, underlining that the combination of mpMRI-targeted and TRUS-guided biopsy is the most accurate strategy for detecting clinically significant prostate cancer.
In summary, both EAU 3 and NCCN 51 guidelines on prostate cancer are cautious in suggesting routine use of mpMRI in the biopsy-naive population, but most high-quality evidence supports the addition of mpMRItargeted biopsy in the diagnostic pathway. Specifically, EAU guidelines on prostate cancer suggest the use of mpMRI before prostate biopsy in this population (but the grade of recommendation is weak), supporting the use of mpMRI-targeted biopsy in addition to TRUSguided biopsy and avoiding biopsy when mpMRI is negative only in patients in whom clinical suspicion of prostate cancer is low 3 .
mpMRI after previous negative biopsy
Much effort has been made in the past decade to improve the management of patients with previous negative biopsies and a persistent clinical suspicion of prostate cancer. The addition of anterior apical cores, performing sampling of areas adjacent to previously biopsied sites and generally increasing the number of cores taken have been the techniques most commonly used to decrease the risk of missing prostate cancer during a repeat biopsy [71] [72] [73] [74] . Saturation biopsy has a higher prostate cancer detection rate than standard 12-14 core TRUS-guided biopsy (32.7% versus 24.9%, www.nature.com/nrurol 12-core TRUS-Bx Detection of csPCa was higher in the MRI-TBx + TRUS-Bx arm than in the 12-core TRUS-Bx arm (73% versus 38%) 62 Biopsy-naive 2016 10-core or 12-core TRUS-Bx + MRI-TBx
Matched cohort RCT (130) 12-core TRUS-Bx Overall, significant differences in the detection of PCa and csPCa were observed between the two arms (64% versus 57%, P = 0.5 and 55% versus 45%, P = 0.8, respectively) 63 Biopsy-naive 2015 2-core MRI-TBx +
TRUS-Bx
Matched cohort RCT
12-core TRUS-Bx • Overall, the PCa and csPCa detection rates did not differ significantly between arms (59% versus 54%, P = 0.4 and 44% versus 49%, P = 0.5, respectively) • 2-core MRI-TBx and 12-core TRUS-Bx detection rates of csPCa were similar, suggesting the increased efficiency of the former in terms of number of cores 64 Biopsy naTure revIeWS | UROlOgY R e v i e w s volume 17 | January 2020 | 49 P = 0.0075) 71 , but the majority of additional cancers identified are clinically insignificant (40% of all prostate cancers detected) 75 . Moreover, the increased rate of complications needs to be considered when further biopsy approaches are being contemplated 76 . The role of mpMRI in this setting is to detect suspicious areas that might have been missed by a previous biopsy and enable targeted biopsies of these suspicious areas to be performed. In the PICTURE study, Simmons et al. 77 evaluated the accuracy of mpMRI in the repeat biopsy setting in a cohort of patients referred for a 5-mm template transperineal biopsy as the reference test. mpMRI-targeted biopsy had a sensitivity of 94% and a NPV of 69% for detecting Gleason score ≥3 + 4 prostate cancer and/or maximum cancer core length ≥4 mm using a Likert score ≥3 as a cut-off value. Notably, only 30% of the patients in this cohort had not had previous detection of cancer; the remaining men previously had low-risk prostate cancer identified using TRUSguided biopsy. Owing to this population heterogeneity, the results regarding mpMRI accuracy in this study should be interpreted with caution. In a meta-analysis of 14 studies, including 698 patients with previous negative biopsy, mpMRI-targeted biopsy had a pooled sensitivity of 88% and specificity of 69% 78 . A meta-analysis and a systematic review 22 evaluating the use of targeted biopsy in the population with a previous negative biopsy 60 both reported that mpMRI improved the detection rate of any prostate cancer and that mpMRI-targeted biopsy was non-inferior to even saturation biopsy techniques for detecting clinically significant prostate cancer 79 (TABle 1) . Another study showed that use of mpMRI-targeted biopsy resulted in the detection of less prostate cancer overall than TRUS-guided biopsy (34% of patients versus 39%) but of more clinically significant disease (26% of patients versus 17%) 80 . Arsov et al. 81 randomly assigned 267 patients to either mpMRI-targeted biopsy (arm A) or a combination of mpMRI-targeted biopsy and TRUSguided biopsy (arm B). In arm B, mpMRI-targeted biopsy alone identified a similar proportion of clinically significant disease to TRUS-guided biopsy (26% versus 25%, P = 0.6). Furthermore, detection of clinically significant prostate cancer was similar in arm A and arm B (29% versus 32%, P = 0.7). The authors concluded that an mpMRI-targeted biopsy alone strategy should be evaluated in patients referred for repeat biopsy after previous negative biopsy.
In summary, the use of mpMRI in the repeat biopsy setting is strongly recommended by the EAU and NCCN guidelines on prostate cancer 3, 51 to reduce the proportion of clinically significant prostate cancer that is missed using standard biopsy modalities. Performing targeted biopsy alone in this setting could be considered to reduce the potential harm of repeated sampling, as is suggested in the EAU guidelines on prostate cancer 3 .
Available biopsy strategies
Different techniques and strategies for performing mpMRI-targeted biopsies have been developed and refined alongside the development of mpMRI. This process has involved software and device development as well as the assessment of different approaches (such as transrectal and transperineal) and strategies (including mpMRI-targeted biopsy alone or combined with the TRUS-guided approach).
Targeted biopsy strategies
An mpMRI-targeted biopsy is defined as any biopsy technique in which an MRI scan is used to determine the location of a suspicious target before biopsy and the resulting information is used to alter the biopsy technique 82 . To date, three approaches of MRI-targeted biopsy have emerged: visual registration (also referred to as cognitive registration); software-assisted registration (also referred to as image fusion registration); and direct in-bore biopsy 83 .
Visual registration. In the visual registration MRI-targeted biopsy technique, a real-time transrectal ultrasound probe is used to image the prostate and biopsy needle. The locations of the suspicious lesions detected on mpMRI are used by the operator to direct the biopsy needle during the targeted sampling to parts of the prostate on the ultrasonography image that relate to the suspicious area on the mpMRI 14 . The visual registration approach is the simplest method of performing mpMRI-targeted biopsy as it does not require any additional equipment to that needed to perform a prostate biopsy without targeting. However, in order to accurately target the suspicious area, the operator needs to be skilled in estimating the location of the lesion on the ultrasonography images. This particular technique is affected by a learning curve effect 84 . Moreover, the operator needs either a multidisciplinary radiologist-urologist approach or a previous training in mpMRI interpretation in order to be able to transpose the radiological information onto ultrasonography images.
Software registration.
Efforts to improve targeted biopsy strategies have led to the development of a softwareregistered targeted technique. This technique enables the contouring of the suspicious lesion and the prostatic gland on mpMRI images by using specific software. The contours are then superimposed onto the ultrasonography images, enabling the operator to identify the area to target. The aim of software-registered targeted biopsy is to overcome the limitations of the visual registered strategy, helping the operator to easily identify the mpMRI-suspicious lesion on ultrasonography images of the prostate and providing improved reproducibility. However, a learning curve effect related to the use of software registration seems to still be present [84] [85] [86] . One disadvantage of this technique is related to the cost of the software platforms, which make it less cost-effective than the visual registration approach 87 . To date, several platforms have been developed (UroNav, InVivo; Artemis, Eigen; Urostation, Koelis; Biopsee, Medicom; Virtual Navigator, Esaote; BioJet, BK Ultrasound), but direct comparisons of the effectiveness of available platforms have not been carried out 88, 89 .
In-bore biopsy. The in-bore biopsy technique is performed inside the MRI scanner itself using sequential mpMRI images to guide the needle into the suspicious area. One advantage of this strategy is that it reduces www.nature.com/nrurol some of the registration error associated with real-time TRUS, which is used in the other mpMRI-targeted biopsy techniques. Both visual-registration and software-registration targeted biopsy can fail to sample the target for several reasons (such as prostate movement and/or deformation, patient movement, incorrect image registration or mismatch image planes) in up to 40% of mpMRI-targeted biopsies negative for the presence of prostate cancer 90, 91 . In addition, the needle can actually be seen inside the lesion on MRI, increasing the likelihood of sampling the correct area. However, this approach is subject to increased costs and scanner use time and requires the involvement of radiologists with expertise in the technique 14 .
Comparative studies. To date, no consensus has been reached regarding which mpMRI-targeted biopsy strategy has the highest rates of detection of clinically significant cancer. A meta-analysis including 43 studies reported no significant differences in the detection of clinically significant prostate cancer among the three different MRI-targeted biopsy techniques; however, a trend towards the superiority of software-registered and in-bore techniques over the visual registered technique was observed (pooled sensitivity for clinically significant prostate cancer 0.89 and 0.92, respectively, versus 0.86, P ≥ 0.42) 83 . Stabile et al. 84 reported the superiority of software-registered targeted biopsy over visual registered targeted biopsy in detecting clinically significant prostate cancer. Software-registered targeted biopsy had a 2.4-fold higher probability of detecting clinically significant prostate cancer than visual registered targeted biopsy. The results of the FUTURE study, in which 234 men were randomized to undergo one of the three strategies, showed no differences in the detection of clinically significant cancer between strategies 92 . However, these results must be considered with caution, as this study was probably unpowered owing to the small sample size and the number of targeted cores taken differed among groups, possibly affecting the detection of prostate cancer. The SmartTarget Biopsy Trial reported similar results, showing no differences between visual registration and software registration techniques. In this within-person randomized paired study, 141 men with a previous prostate biopsy and a positive mpMRI received, in a randomized order, both a visual-registration and a software-registration targeted biopsy in the same session 93 . Nevertheless, considering that the reported Gleason grade concordance between mpMRI-targeted biopsy and prostatectomy specimens is good but not perfect (88-90%) 94, 95 , a proper and reliable comparison between different mpMRI-targeted biopsy techniques should be conducted, using final pathology as the reference standard.
The transrectal versus the transperineal approach. Each mpMRI-targeted biopsy technique can be performed using either a transrectal or a transperineal approach ( fig. 5 ), although the most commonly used approach to mpMRI-targeted biopsy is currently transrectal 59 . Some of the factors influencing choice of a specific approach include the likelihood of infection, diagnostic accuracy and feasibility. The transrectal approach has a non-negligible risk of sepsis and prophylactic fluoroquinolones are currently recommended 96, 97 . Worryingly, rates of resistance to fluoroquinolones are rising in rectal flora and increasing evidence shows that their use has a detrimental effect in the long term (such as disabling and potentially permanent adverse effects on tendons, muscles, joints, nerves and the central nervous system, and an increased rate of sepsis owing to bacterial resistance) 98 . However, rates of hospitalization related to sepsis from a transperineal approach are extremely low compared with those related to the transrectal approach (0-0.7% versus 0.5-6.9%) 96 .
Both the transrectal and transperineal approaches have acceptable accuracy for mpMRI-targeted biopsy 83 . Pepe et al. 99 conducted a direct comparison of transrectal and transperineal mpMRI-targeted biopsy. Transperineal fusion biopsy resulted in more clinically significant prostate cancer being detected than trans rectal cognitive biopsy (93% versus 67% of the total number of clinically significant prostate cancer that was detected by the reference standard), with the former detecting more anterior cancers (94% versus 25% of all anterior cancers diagnosed. However, as different mpMRItargeted biopsy strategies (fusion and cognitive) were compared, concluding whether the results were caused | Transrectal versus transperineal approach to biopsy. Each multiparametric MRI (mpMRI)-targeted biopsy technique can be performed using either a transrectal or a transperineal approach, but mpMRI-targeted biopsy is currently most commonly performed using the transrectal approach. Factors influencing choice of a specific approach include likelihood of infection, diagnostic accuracy and feasibility. A nonnegligible risk of sepsis exists using the transrectal approach and prophylactic fluoroquinolones are currently recommended, but rates of resistance to fluoroquinolones are rising in rectal flora and increasing evidence shows that their use has a detrimental effect. However, rates of hospitalization related to sepsis from a transperineal approach are extremely low. Both the transrectal and transperineal approach have acceptable accuracy for mpMRI-targeted biopsy. Reproduced from ref. 100 , Springer Nature Limited. naTure revIeWS | UROlOgY by the different strategy or the different approach is difficult. Stabile et al. 84 reported the results of a comparison between the transperineal or transrectal approach using software-registered targeted biopsy. The transperineal approach had a higher detection rate of clinically significant prostate cancer than the transrectal approach (the transperineal approach odds ratio for detection of clinically significant prostate cancer was 4.1, with the transrectal approach as reference), with the latter being subject to a more evident learning curve effect. However, transrectal mpMRI-targeted biopsy has been shown to have excellent detection rates of clinically significant prostate cancer and can detect anterior tumours when performed by an experienced clinician 46, 68 . The feasibility of delivering these different approaches is another factor that requires consideration. Biopsies carried out transrectally are traditionally performed under local anaesthesia within the office or outpatient setting, and most centres can deliver this approach without too much difficulty. However, transperineal biopsy is more time-consuming than transrectal biopsy, is resource-intensive and is usually done under general anaesthesia, requiring operating room time. These factors reduce the feasibility of performing transperineal mpMRI-targeted biopsy for the average centre. However, with the increasing use of local anaesthetic in transperineal biopsy and the advantages with respect to infection risk and diagnostic accuracy, this approach is likely to become increasingly popular 100 .
In summary, the evidence is not strongly in favour of one approach over another for mpMRI-targeted biopsy; however, software registration and in-bore targeted biopsy might provide good detection of clinically significant prostate cancer when relying on locally available equipment and expertise. One method of targeting might have advantages over others for particular lesions in particular locations, although these indications remain to be elucidated. Regarding the access route, in the presence of risk factors for urinary infections (such as indwelling catheter or need for saturation biopsy), a transperineal approach can be considered to reduce the risk of infectious complications.
mpMRI alone or in combination
One of the most debated questions regarding the use of mpMRI-targeted biopsy is whether, in the presence of a positive mpMRI, a targeted approach alone might be sufficient. mpMRI-targeted biopsy alone was shown to have superior efficacy to TRUS-guided biopsy in the PRECISION study 46 . mpMRI-targeted biopsy alone detected more clinically significant prostate cancer than TRUS-guided biopsy (38% versus 26%) and fewer insignificant cancers (9% versus 22%) with fewer cores (median 4 versus 12). Moreover, the rate of complications at 30 days was lower in the mpMRI-targeted biopsy group 46 . However, most studies seem to show that the combination of systematic and targeted biopsy increases the detection of both any prostate cancer and clinically significant prostate cancer 59, 83, 101, 102 .
Supporters of an mpMRI-targeted biopsy alone strategy argue that the proportion of clinically significant prostate cancer missed is low, as the systematic approach detects approximately double the number of insignificant cancers as mpMRI-targeted biopsy 22, 83, 103 , which highlights an advantage of avoiding systematic biopsy, reducing overdiagnosis and potentially overtreatment. Overdiagnosis and overtreatment in prostate cancer is a major problem and biopsy techniques that reduce this must be taken into consideration when deciding on the optimal approach 4,104 . Other advantages of the mpMRItargeted biopsy alone approach include the reduction in core number, operative time, pathologist time and patient-reported complications (which can lead to considerable morbidity, particularly for transperineal systematic biopsies) 46, 77 .
Supporters of the combined approach argue that obtaining histological information about prostate areas that are not suspicious on mpMRI is important as it can influence the margins and nerve-sparing approach in radical surgery 105 . Furthermore, as prostate cancer is a multifocal disease 106 , supporters of the combined approach argue that not sampling outside of the area targeted using mpMRI can result in smaller prostate cancer foci that surround the index lesion being missed 107, 108 , although the clinical significance of these lesions is debated. Stabile et al. 109 reported that the probability of finding clinically significant prostate cancer foci outside the lesion detected using mpMRI is directly related to the PI-RADS score obtained 109 , ranging from 25% for a PI-RADS score of 3 to 70% for a PI-RADS score of 5 (ref. 109 ). In summary, the decision to perform a targeted alone approach omitting systematic sampling must be discussed with the patient, taking into account the risk (ranging from 5% to 20%) of misdiagnosing significant disease but at the same time significantly decreasing the risk of insignificant cancer overdiagnosis 65, 103 . What is clear is that patient preferences should be considered when deciding on which biopsy approach to adopt, bearing in mind the advantages and limitations.
The role of mpMRI as a triage test
In order to use mpMRI as a triage test in the prostate cancer diagnostic pathway, it needs to reliably predict the presence or absence of cancer; a high NPV might help to avoid prostate biopsies. In the biopsy-naive population included in the PRECISION trial 46 , the use of an upfront mpMRI enabled 28% of patients (in the investigative arm) to avoid biopsy, although follow-up monitoring of these patients is ongoing. In the PROMIS study 47 , 27% of patients had a negative mpMRI and the authors suggested that these patients could have avoided biopsy. The introduction of mpMRI as a triage test might change the traditional diagnostic pathway of prostate cancer ( fig. 6 ).
Using a negative mpMRI
The role and the clinical utility of a negative mpMRI is strictly related to its NPV, hence its reliability for the absence of clinically significant prostate cancer. The NPV of mpMRI has been assessed, but it varies widely among the published series. This wide variation reflects the differences in the prevalence of cancer-free prostates in different populations. In the PROMIS study 47 , which was designed to provide level 1 evidence on the www.nature.com/nrurol diagnostic accuracy of mpMRI, the performance of mpMRI was compared with TRUS-guided biopsy in 576 biopsy-naive men using a 5-mm-template transperineal biopsy as the reference standard. The NPV of mpMRI for Gleason score ≥4 + 3 and/or a maximum cancer core length ≥6 mm of any cancer was 89%. Notably in this multicentre study, a negative MRI was not associated with any primary Gleason pattern 4 disease or worse. Most of the thresholds for declaring a miss were triggered by maximum cancer core length rather than grade. However, the NPV dropped to 76% when the a priori threshold of any pattern 4 or a maximum cancer core length ≥4 mm was used. Despite these results, mpMRI had a better NPV than the traditional standardof-care modality of TRUS-guided biopsy, which had an NPV of 63% (P < 0.0001). Nonetheless, the limitations of the PROMIS study 47 should be acknowledged. First, no information was provided regarding tumour location. This omission might have created a mismatch of tumours detected by mpMRI and by transperineal biopsy. Indeed, some mpMRI-suspicious lesions might have been negative for prostate cancer and, vice versa, some negative areas on mpMRI might have been positive for the presence of cancer. Second, the diagnostic accuracy of TRUS-guided biopsy might have been decreased as it was performed after a 5-mm-template transperineal biopsy, which might have considerably modified the prostate parenchyma because up to 70 cores were taken.
Panebianco et al. 110 assessed the value of a negative mpMRI after 48 months of follow-up monitoring in 1,545 patients. The probability of being free of clinically significant prostate cancer at 48 months was 95% in biopsy-naive men and 96% in men with a previous negative biopsy 110 . However, in this study, which was a reflection of clinical practice, not all patients had routine prostate biopsies carried out as part of follow-up monitoring; thus, the true prevalence of clinically significant prostate cancer might have been higher than reported.
A meta-analysis 111 evaluating the NPV of mpMRI in 48 studies (including 9,613 patients) reported a median NPV for any prostate cancer of 82.4% (IQR 69-92) and of 88.1% (IQR 86-92) for clinically significant prostate cancer. The large variability in the NPV was a result of the lack of standardization in the definition of clinically significant disease and differences in the prevalence of clinically significant prostate cancer, which ranged from 14% to 51%. The authors concluded that, should it be possible to risk-stratify men into those with a high and low pre-test probability of having clinically significant prostate cancer, mpMRI could be used as a triage test in patients at low risk.
A negative mpMRI should not be considered enough to omit prostate biopsy owing to the wide variability of mpMRI NPV. However, a negative mpMRI should be used as a further clinical tool to help in the decisionmaking process for prostate cancer diagnosis. The combination of negative mpMRI with nomograms predicting the presence of prostate cancer should be supported in order to identify those patients who might safely avoid a biopsy. The decision-making needs to be shared with the patient.
Using a positive mpMRI
A positive mpMRI can also be used to influence the biopsy technique. Notably, the PPV of mpMRI ranges from 48% to 82% for any prostate cancer using a cutoff value of a Likert score of ≥3 and a PPV of 42-92% when using a cut-off value of a Likert score of ≥4 (ref. 111 ). Similarly, using the PI-RADS score, PPV ranges from 50% to 83%, using a cut-off value of ≥3 (ref. 44 ). The PROMIS study reported a PPV of 65% for Gleason score ≥3 + 4 (ref. 47 ). These results highlight the large number of false positives obtained using mpMRI, which means that a positive mpMRI alone cannot currently replace prostate biopsy. One of the main causes of the false positives are suspicious areas on mpMRI that mimic prostate cancer but are, in fact, indicative of benign conditions such as prostatitis 26, 112 . The development of clinical adjuncts to a positive mpMRI that help differentiate between areas likely and not likely to be clinically significant prostate cancer are important fields of research. Further, riskstratifying mpMRIs scored as indeterminate or a Likert or PI-RADS score of 3 is a particularly important area of focus to enable a definitive management plan to be implemented.
Adjuncts to mpMRI
Several aspects and factors of mpMRI are subject to continuous development and refinement. Some of these (such as magnetic field strength, endorectal coil, spectroscopy and mpMRI cost-effectiveness), are still debated, others mostly concern different strategies and 
Magnetic field strength
Current clinical practice uses mpMRI scanners with magnetic field strengths of either 1.5 T or 3 T are typically used in current clinical practice. An increased signal:noise ratio is provided by 3 T scanning, which enables increased spatial and temporal resolution 113 . However, increased field strengths might cause more artefacts. Initial studies comparing 1.5 T with 3 T mpMRI reported comparable accuracy in cancer localization and local staging 114, 115 . Moreover, 1.5 T, performed using both endorectal and surface coils, seemed to show superior image quality and tumour delineation compared with 3 T. Direct comparisons in homogeneous cohorts without the use of endorectal coil showed that the use of 1.5 T did not compromise the diagnostic accuracy of mpMRI in terms of PI-RADS scoring, achieving excellent NPV and moderate PPV (94% and 52%, respectively) 116, 117 . Furthermore, no significant differences between the two field strengths were observed in a meta-analysis 45 . Further data are needed, but the PI-RADS v2 recommendations state that, overall, the advantages of 3 T substantially outweigh any disadvantages and the authors prefer and recommend the use of 3 T systems. A 3 T system is not deemed mandatory for prostate mpMRI, but using such systems seems reasonable for prostate mpMRI when available in a given practice.
The use of an endorectal coil
Prostate mpMRI can be performed using two types of coil: endorectal and external (surface) phased array coil. The combination of both or a surface coil alone are commonly used in clinical practice ( fig. 7) . The addition of an endorectal coil is associated with increased costs and duration of examination and is uncomfortable for patients. Evidence is conflicting on the benefit of an endorectal coil in the diagnosis and staging of clinically significant prostate cancer. Some systematic reviews and meta-analyses show no clear benefit of using an endorectal coil 22, 45, 53 . However, other studies have shown that the addition of an endorectal coil to a surface coil can improve the accuracy of mpMRI in the detection, localization and staging of prostate cancer [118] [119] [120] [121] . Specifically, Turkbey et al. 119 demonstrated an increase in sensitivity from 0.45 to 0.76 and in PPV from 0.64 to 0.80 with the addition of an endorectal coil. Nevertheless, these studies were affected by several limitations, such as the non-blinding of radiologists, variable quality in surface coils and small cohorts. Owing to the aforementioned issues and the controversial clinical benefit, the use of an endorectal coil is not considered mandatory in the guidelines 25 .
Utility of spectroscopy
A number of studies have evaluated the value of MRSI in the diagnosis of prostate cancer. Contradictory results have been reported on the diagnostic benefit of MRSI 78, [122] [123] [124] [125] . The majority of studies assessed MRSI in combination with PI-RADS v1 scoring, although one study evaluated the effect of integration of MRSI to PI-RADS v2 and reported improvement in detection of high-grade prostate cancer (accuracy of 0.65 versus 0.72) 126 . MRSI is a complex technique, with low availability, high costs, long acquisition time, a need for experienced radiologists and dedicated software. Owing to these limitations and the unclear clinical benefit, MRSI is not currently mandated in the clinical guidelines 25 .
The use of quantitative assessment
Despite the development of standardized reporting systems, accurate interpretation of mpMRI remains challenging, particularly for inexperienced radio logists. To overcome this issue, a quantitative approach to mpMRI interpretation has been developed, which has been established by defining thresholds for quantitative radiological parameters indicative of prostate cancer. Potential parameters include the tenth percentile of a b Fig. 7 | Comparison between T2-weighted images of a prostate with and without the use of an endorectal coil. An endorectal coil as an adjunct to multiparametric MRI (mpMRI). mpMRI of nonmalignant prostate gland (T2-weighted sequence) performed with (part a) and without (part b) the use of an endorectal coil. The use of the endorectal coil enables improved resolution of images and improved identification of anatomical structures. Nonetheless, the use of an endorectal coil is still controversial.
www.nature.com/nrurol ADC, the time to peak, the T2 signal intensity skewness and the T2 value in the peripheral zone [127] [128] [129] . However, investigation of these associations is still at the experimental stage. The main concern about the applicability of quantitative sequences is their generalizability for different protocols and mpMRI vendors. In conclusion, a need for improvement remains in standardization and mpMRI reproducibility. Further assessment and development of quantitative mpMRI will result in improved and standardized mpMRI interpretation. The specific role and advantages behind the use of mpMRI adjuncts, particularly the role of quantitative analyses, still need to be clarified. Further dedicated, well-designed studies will help to make mpMRI an extensively usable test.
Active surveillance and mpMRI
Active surveillance (AS) has been increasingly adopted as a conservative management approach for patients with low-risk prostate cancer and selected men with intermediate-risk prostate cancer to avoid or delay unnecessary treatment until higher-risk disease is evident 130 . Several AS programmes are available, with different selection criteria [131] [132] [133] . Growing evidence suggests that mpMRI is being increasingly used in the setting of AS [134] [135] [136] . A systematic review showed that mpMRI is useful for detecting clinically significant prostate cancer in men eligible for AS, reporting that 70% of these men have a positive mpMRI 134 . Interestingly, a 2018 systematic review, including men with low-risk prostate cancer (Gleason score 3 + 3), showed that, at confirmatory biopsy, a diagnostic pathway including a combination of mpMRI-targeted biopsy and TRUS-guided biopsy yielded a higher rate of cancer upgrading (27%) than either strategy alone (upgrading for mpMRI-targeted biopsy alone versus TRUS-guided biopsy was 17% versus 20%). Nonetheless, no pathway was more favourable than the other (relative risk 0.92). The authors concluded that both biopsy techniques were complementary in detecting prostate cancer upgrading and that a prebiopsy mpMRI should be performed before a confirmatory biopsy for men on AS 135 . However, at present, no robust data support the use of mpMRI instead of repeat standard biopsy for monitoring men on AS 137, 138 . Many studies reporting the utility of mpMRI as a monitoring tool for men on AS lack rigor and do not readily enable comparison of outcomes. Thus, the European School of Oncology convened a task force to establish the PRECISE guidelines for the reporting of serial mpMRI on AS 139 . The key points of these recommendations are that the likelihood of mpMRI change over time (such as mpMRI sequences and scoring) from the previous or baseline mpMRI scan must be assessed and that absolute measurements of eventual visible lesion size must be taken at each time point to enable accurate assessment of change, using a dedicated pictorial representation.
Role of biomarkers to improve mpMRI
The use of biomarkers in combination with mpMRI information to improve the accuracy of mpMRI is being investigated. PSA density (PSAd), PCA3 and prostate health index (PHI) are the most commonly studied biomarkers in combination with mpMRI (TABle 2) . PSA density is known to be related to the presence of clinically significant prostate cancer 140, 141 . Washino et al. 142 retrospectively reviewed 288 biopsy-naive patients who underwent both mpMRI and mpMRI-targeted plus TRUS-guided prostate biopsy for suspected prostate cancer for whom PSAd were available. PI-RADS v2 was used for reporting. The authors reported an accuracy of mpMRI alone and PSAd alone in predicting prostate cancer of 0.82 and 0.84, respectively. The combination of PI-RADS score ≤3 plus PSAd <0.15 ng/ml/ml, yielded no clinically significant prostate cancer. However, a PI-RADS score ≥4 and a PSAd ≥0.15 ng/ml/ml, or a PI-RADS score = 3 and a PSAd ≥0.30 ng/ml/ml yielded the highest clinically significant prostate cancer detection rates (ranging from 76 to 97%) 142 .
The addition of PSAd increased the accuracy of mpMRI alone from 0.75 to 0.79 in a cohort of 1,040 patients with suspected prostate cancer 143 . The NPV of PI-RADS score 3 as a cut-off increased from 92% to 98% using a PSAd of 0.15 ng/ml/ml as the threshold, potentially avoiding 20% of unnecessary biopsies 143 . Hansen et al. 144 reported similar findings in the repeat biopsy setting using a PSAd threshold of 0.20 ng/ml/ml and a Likert score threshold of 3. Appayya et al. 49 assessed the performance of PSAd in patients with indeter minate lesions (a Likert score of 3). Overall, clinically significant prostate cancer was detected in 21 of 76 men (27%). A PSAd cut-off value of 0.17 ng/ml/ml resulted in a sensitivity, specificity and NPV of 0.67, 0.75 and 0.85, respectively 49 . According to these results, the PSAd is a cost-free, useful clinical tool when used in combination with mpMRI in order to improve the accuracy of detecting clinically significant prostate cancer, helping in the decision-making process before prostate biopsy.
Another biomarker that has been assessed in combination with mpMRI is urinary PCA3 level. PCA3 is a biomarker that can be detected in urine, which showed a good sensitivity and specificity for identification of prostate cancer in patients with previous negative biopsies 145 . Busetto et al. 146 demonstrated that the addition of urinary PCA3 level to mpMRI information increased the diagnostic accuracy (area under the curve (AUC)) of a multivariate model from 0.78 to 0.81 in 171 patients with previous negative biopsies 146 . However, the studies examining the use of urinary PCA3 level for this purpose were affected by limitations such as small sample size, unclear use of PI-RADS scoring and TRUS-guided biopsy as the reference standard. Moreover, the availability and the cost-effectiveness of this test should be considered.
The PHI is a marker incorporating pro-2PSA, free PSA and total PSA into a mathematical algorithm ((p2PSA/fPSA) × PSA 0.5 ) 147 . Increased PHI values are associated with an increased risk of the presence of clinically significant prostate cancer 148, 149 , and its use has been demonstrated to enable avoidance of up to 30% of biopsies at the cost of missing a small proportion of significant disease (10%) using a cut-off of 28.6 (ref. 150 ). Gnanapragasam et al. 151 evaluated the role of PHI in combination with mpMRI in a series of 279 men with a history of previous negative biopsy. The addition of naTure revIeWS | UROlOgY PHI to mpMRI increased the predictive performance of mpMRI both for any prostate cancer (AUC 0.71 versus 0.64) and clinically significant prostate cancer (0.75 versus 0.64). Similarly, Druskin et al. 152 showed that the addition of PHI to a multivariate model including age, biopsy history and PI-RADS score increased the AUC for clinically significant prostate cancer detection from 0.83 to 0.90 in a cohort of 109 patients.
The use of these biomarkers in combination with mpMRI should be considered. To date, PSAd seems to be the most efficient biomarker available, owing to low costs and easy accessibility.
Cost-effectiveness
The introduction of mpMRI within the prostate cancer diagnostic pathway has advantages from a diagnostic perspective, but assessing its cost-effectiveness is important. One of the earliest studies addressing this topic was conducted by de Rooij et al. 153 , who developed a model based on two diagnostic strategies: standard of care based on performing TRUS-guided biopsy in patients with suspected prostate cancer and an experimental mpMRI strategy based on offering mpMRI to men referred for suspected prostate cancer, with subsequent mpMRI-targeted biopsy if the mpMRI is positive, or routine follow-up monitoring if mpMRI is negative. In both arms, patients underwent active treatment (radical prostatectomy or radiotherapy) when clinically significant prostate cancer was diagnosed. The outcomes were costs, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). The authors concluded that, although the experimental mpMRI strategy is initially more expensive (expected costs of the mpMRI strategy were €31 higher than those for the TRUS-guided biopsy strategy), these extra costs are compensated for by the reduction in treatment costs resulting from fewer false positives and an improved estimation of tumour aggressiveness compared with the standard of care TRUS-guided biopsy pathway. This resulted in an over-time improvement in QALYs related to mpMRI strategy achieved by avoiding unnecessary radical treatment of diseases that are not clinically significant (with a reduced quality of life without an improved survival) and decreasing the likelihood of late diagnosis 153 . A similar study was carried out by Faria et al. 154 relying on data from the PROMIS study cohort. In order to establish how to best combine different diagnostic tests (that is, TRUS-guided biopsy, template prostate-mapping biopsy and mpMRI-targeted biopsy) in order to provide the most cost-effective strategy, the combination of each test and mpMRI cut-offs resulted in a total of 383 possible diagnostic strategies. The most cost-effective strategy for detecting clinically significant prostate cancer was the use of mpMRI as the first test followed by a trans rectal mpMRI-targeted biopsy in men in whom the mpMRI suggests the presence of prostate cancer and a second transrectal mpMRI-targeted biopsy if no prostate cancer is found 154 . Similar findings in Italian 155 , Canadian 156 and US 157 health-care setting studies highlighted that an mpMRI-based pathway can be cost-effective in a range of settings, although one of the main assumptions in these models is that a negative mpMRI is used as a triage test to avoid biopsy [155] [156] [157] . This strategy is not widely embraced owing to the probability of missing clinically significant prostate cancer in men with negative mpMRI who did not receive a biopsy (TABle 3) .
Limitations in the use of mpMRI
Despite the benefits to the prostate cancer diagnostic pathway, distinct challenges remain. Interpretation remains a problem, despite improvements in interobserver variability as a result of formal scoring systems, such as PI-RADS 158 . Entities that have similar characteristics to prostate cancer are frequently encountered. These entities can be normal anatomical structures or pathological benign conditions and include the periprostatic venus plexus, neurovascular bundles, post-biopsy haemorrhage, BPH nodules, acute or chronic prostatitis, and abscesses 26, 112, 159 . As not all of these entities are recognized in the PI-RADS v2 guidelines 158 , the experience of radiologists becomes crucial in differentiating benign from malignant conditions. The importance of reader training in reporting prostate mpMRI has been assessed in several studies that demonstrated the presence of a steep learning curve [160] [161] [162] [163] . In all the series evaluated, a considerable improvement was observed in the diagnostic accuracy of novice readers between pretraining and post-training reports. Specifically, Rosenkrantz et al. 164 demonstrated an initial rapid improvement in accuracy seen after 40 examinations. In this study, six second-year radiology residents (with no previous experience of prostate mpMRI) reviewed 124 prostate mpMRIs. Overall, three of the six readers received feedback after each examination showing the solution of the preceding case. Accuracy improved from 58.1% to 75.3% (P = 0.027) without feedback and from 58.1% to 77.4% (P = 0.046) with feedback. The effect of the feedback was not significantly associated with the accuracy improvement (P = 0.891) suggesting the presence of a self-guided learning mechanism. Nonetheless, the authors suggest the use of training with feedback in order to increase reader's confidence in reporting mpMRI 164 .
When evaluating the reproducibility of mpMRI, disagreement exists, even among experienced radiologists 161, 165 . In particular, in a study evaluating the interobserver agreement among six radiologists from different institutions, the overall agreement level for PI-RADS v2 cut-off scores of ≥3 and ≥4 was 79% and 78%, respectively 161 . In the PRECISION trial, a subanalysis focusing on mpMRI central quality control had similar results, reporting 78% agreement 46 . However, naTure revIeWS | UROlOgY for staging purposes, for which no formal standardized reporting system has yet been provided, the level of agreement is even lower (κ coefficient = 0.36 for ECE) 166 . Currently, mpMRI is used widely in academic centres but is less frequently used in non-academic centres. Evidence supporting its diagnostic performance primarily originates from academic centres and its reproducibility if used more widely is uncertain. The PROMIS trial involved nonacademic centres and used only a 1.5 T MRI machine in order to increase the generalizability of the findings 47 . The PRECISION trial also included some non-academic centres and allowed a range of different access routes and registration methods, increasing the generalizability of the findings to other centres 46 . A further study has been carried out in non-academic settings without the dedicated training programme used in PROMIS and a diagnostic performance similar to that seen in the PROMIS trial has been demonstrated (mpMRI sensitivity, PPV and NPV in detecting clinically significant prostate cancer were 73.2%, 41.4% and 85.4%, respectively) 167 . The results of this study are encouraging for the potentially widespread use of mpMRI, as the authors showed that obtaining good diagnostic performance is feasible in a non-academic centre 167 . Other issues include the need to increase the capacity to deliver mpMRI, meeting the training needs of clinicians involved and delivering an mpMRI diagnostic pathway within the varying health-care system funding models that currently exist.
An effort towards overcoming these barriers to the widespread use of mpMRI is needed. Extensive training programmes for mpMRI reporting aimed at both radiologists and urologists and improved clarification of the cost-effectiveness of mpMRI are pivotal in increasing the proportion of men who can benefit from this useful diagnostic test.
Future directions
Despite the rapid uptake of mpMRI use for the diagnosis of prostate cancer, a number of outstanding issues with its use remain. First, the role of DCE in addition to other sequences is still under debate. The updated PI-RADS v2 downgraded the role of DCE to a secondary sequence within the evaluation of peripheral zone lesions; however, the panel still suggested its inclusion in a multiparametric protocol 25, 158 . Issues related to the use of DCE are increased costs, the increased time required to perform the study, use of Ga and patient discomfort. To date, many studies have demonstrated that the use of a biparametric imaging protocol (avoiding use of DCE) does not alter diagnostic accuracy and is comparable with multiparametric protocols [168] [169] [170] . Nonetheless, DCE is still proposed as a useful sequence in evaluating indeterminate lesions, small cancers or in challenging location and previously treated prostates. However, given the growing use of mpMRI, especially in the biopsynaive setting, evaluating the possibility of an imaging protocol with improved efficacy is warranted. Further randomized studies might help to definitively prove the feasibility of biparametric MRI.
Second, despite improvements in mpMRI reporting after the introduction of PI-RADS v2, inter-reader variability remains an unsolved problem, particularly when mpMRI is used in centres with little experience. To overcome this issue, during the past 5 years, efforts have been made to implement computer-aided diagnosis (CAD). The aim of CAD is to bypass interobserver variability through the use of machine learning algorithms based on quantitative analyses that are able to discriminate areas within the prostate gland in which clinically significant prostate cancer is suspected [171] [172] [173] [174] [175] [176] . Results regarding the use of CAD in mpMRI of the prostate are still preliminary, but the first comparison between CAD and PI-RADS v2 showed promising results. The AUC for clinically significant prostate cancer of machine learning-based analysis of mpMRI radiomics was higher than PI-RADS v2 (0.955 versus 0.878, P < 0.001 for the transitional zone; 0.972 versus 0.940, P = 0.097 for the peripheral zone). When radiomics was added to PI-RADS, a performance improvement in detecting clinically significant prostate cancer was observed for both the peripheral zone and the transitional zone of the prostate (P < 0.01) 177 . The introduction of CAD into clinical practice could lead to an improvement in the workflow of reporting and in the diagnostic accuracy and could also help urologists to perform targeted diagnostic and therapeutic procedures.
Finally, when analysing the potential causes of overdiagnosis, serum PSA level remains the major factor related to the increased diagnosis of clinically insignificant disease 17 . PSA is affected by a low specificity and low NPV considering that one of four patients with PSA <4.0 ng/ml can harbour clinically significant prostate cancer 178 . Most of the studies aimed at improving the accuracy of screening strategies tested the use of PSA in combination with mpMRI 179, 180 . The results of these studies were promising but relied on cohorts selected with the use of PSA, hence selected with a low specific test that inevitably affected the prevalence of clinically significant and insignificant prostate cancers in these populations. In order to avoid the bias that occurs in the prerisk assessment using PSA, novel diagnostic tests aimed at reducing overdiagnosis (such as prostate mpMRI) should be used a step before the assessment of PSA in the diagnostic pathway. In this context, the clinical question of whether prostate cancer screening based on the use of mpMRI alone is feasible, efficient and accurate needs addressing. One pilot study has been carried out comparing a primary screening using mpMRI with serum PSA level 181 . In a cohort of 47 patients aged between 50 and 75 years who received mpMRI irrespective of PSA level, mpMRI showed greater accuracy than PSA in predicting the presence of prostate cancer (AUC 0.81 versus 0.67) 181 . Larger prospective studies are awaited to provide evidence of the feasibility and the efficacy of an mpMRI screening strategy.
Conclusions
Over the past decade, prostate mpMRI has been an exciting development that seems likely to change the standard prostate cancer diagnostic pathway. This test is useful in a number of different patient populations and has the potential to serve as a triage test. Results of studies comparing mpMRI-targeted biopsy with systematic biopsy www.nature.com/nrurol suggest the addition of mpMRI-targeted biopsy to systematic biopsy and strategies such as mpMRI-targeted biopsy alone are feasible. Use of biomarkers combined with mpMRI information can improve the performance of the mpMRI in identifying clinically significant cancer. Furthermore, the cost-effectiveness of an mpMRI diagnostic pathway has been demonstrated in a number of different settings. However, improvements aimed at reducing inter-reader variability and improving the standardization of mpMRI reporting are important in supporting the introduction of mpMRI and optimizing use of this technology.
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